fbpx
Menu
0
was successfully added to your cart.

Cart

WLWT Reports FDA Removes Black Box Warning on HRT

By February 11, 2026351Face General Category

 

 

 

 

The FDA is making major changes to hormone replacement therapy (HRT) guidelines — including removing long-standing black box warning labels. What does this mean for women navigating menopause? In this segment, Dr. Jon Mendelsohn, Medical Director of Advanced Vitality, and Kati Vincent, APRN, explain why the FDA reversed course, what the original Women’s Health Initiative got wrong, and how properly balanced hormone therapy can safely support women’s health, vitality, and quality of life. They also discuss: Who should and should not consider hormone replacement therapy Why age and timing matter when starting HRT The importance of hormone balance (estrogen, progesterone, and testosterone)

How HRT may support cardiovascular health, cognition, and libido Common fears and misconceptions surrounding menopause treatment If you or someone you love is experiencing menopause symptoms and unsure about hormone therapy, this conversation provides clear, evidence-based guidance. 🔔

Always consult with a qualified medical provider before starting or changing any hormone therapy. ⏱️ Topical Timestamps 00:00 FDA announces removal of black box warnings on hormone therapy 00:48 Why hormone replacement therapy was considered risky 01:02 What the Women’s Health Initiative got wrong 01:29 Estrogen and cardiovascular protection 01:47 The “window of opportunity” for starting HRT 02:12 How FDA changes improve access and confidence 02:41 Addressing fear and misinformation around hormones 02:52 Importance of hormone balance (estrogen & progesterone) 03:12 Who should avoid hormone replacement therapy 03:31 Testosterone use in women — benefits & stigma 03:54 Hormones as a tool for healthy aging

Summary:

The video discusses the FDA’s removal of black box warnings on hormone replacement therapy (HRT), which is often used to treat menopause symptoms (0:00). Dr. Jon Mendelsohn and Kati Vincent explain that the original Women’s Health Initiative study, which led to the warnings, was flawed because it included many older women who may have already developed cardiovascular issues (1:02). They clarify that estrogen can be cardioprotective (1:29), and there’s a “window of opportunity” (1:47) for starting HRT, ideally within 10 years of menopause (1:47).

Key points covered in the discussion include:

  • Improved Access and Confidence (2:12): The FDA’s change is expected to improve access and confidence in HRT for women (2:12).
  • Addressing Misinformation (2:41): It’s important to work with a provider who looks at the “entire picture” to avoid risks associated with hormone imbalances, such as taking estrogen without progesterone (2:41).
  • Who Should Avoid HRT (3:12): Women predisposed to certain cancers, especially estrogen receptor-positive breast cancer, should be cautious (3:12).
  • Testosterone Use in Women (3:31): The benefits of testosterone for women, including increased libido, cognitive function, and cardiovascular health, are also discussed (3:31).
  • Hormones for Healthy Aging (3:54): Hormones are presented as a tool for healthy aging (3:54).